Viewing Study NCT02158520


Ignite Creation Date: 2025-12-25 @ 4:08 AM
Ignite Modification Date: 2026-03-11 @ 10:32 PM
Study NCT ID: NCT02158520
Status: COMPLETED
Last Update Posted: 2020-01-21
First Post: 2014-06-05
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery
Sponsor: Academic and Community Cancer Research United
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Melanoma View
None Mucosal Melanoma View
None Stage IV Cutaneous Melanoma AJCC v6 and v7 View
None Stage IV Uveal Melanoma AJCC v7 View
None Unresectable Melanoma View
Keywords: